Get the option to either outsource your CHO cell line development program (partially orentirely) to Sartorius or access our cell line development technology for your in-house development. In both options, you would be get access to an advance cell line development platform that is industry recognized and regulatory proven.
With outsourcing, Sartorius would be your extended laboratory bench and trusted drug development partner. While with licensing our technology, you would have access to a ready-to-use platform, avoiding lengthy optimization steps and seamlessly rebuild our platform in your labs.
In 2026, we have upgraded our CLD technology with the launch of our novel genetically engineered CHO host cell line with up to 2-fold and 3-fold increase in titer and cell-specificproductivity respectively across different protein molecule types. This cell line was rationally designed through proteomic profiling and CRISPR-mediated gene editing to deliver a more productive host while maintaining product quality and robust stability.
Show all Products
